In addition, tumor-infiltrating Treg will probably also act to suppress surrounding effector immune cells through the activity of CD39 and ultimately adenosine signaling, similar to what is suggested for intratumoral Treg in breast cancer patients based on in vitro experiments [29]. The gene discussed is ENTPD1; the disease is neoplasm.